Loading...

Y-mAbs Therapeutics

Nasdaq:YMAB
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
YMAB
Nasdaq
$779M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The last earnings update was 73 days ago. More info.


Add to Portfolio Compare Print
YMAB Share Price and Events
7 Day Returns
-0.7%
NasdaqGS:YMAB
-1%
US Biotechs
-1.2%
US Market
1 Year Returns
-
NasdaqGS:YMAB
-11.9%
US Biotechs
3.3%
US Market
YMAB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Y-mAbs Therapeutics (YMAB) -0.7% 1.2% -5.6% - - -
US Biotechs -1% -3.6% -0.7% -11.9% 5.4% 7.4%
US Market -1.2% 0.8% 0.9% 3.3% 35.9% 41.7%
1 Year Return vs Industry and Market
  • No trading data on YMAB.
  • No trading data on YMAB.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Y-mAbs Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Y-mAbs Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $22.78.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Y-mAbs Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Y-mAbs Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:YMAB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.69
NasdaqGS:YMAB Share Price ** NasdaqGS (2019-07-19) in USD $22.78
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.44x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.86x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Y-mAbs Therapeutics.

NasdaqGS:YMAB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:YMAB Share Price ÷ EPS (both in USD)

= 22.78 ÷ -1.69

-13.49x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Y-mAbs Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Y-mAbs Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Y-mAbs Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGS:YMAB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.49x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
11.7%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 0.79x
United States of America Market PEG Ratio Median Figure of 2,119 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Y-mAbs Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Y-mAbs Therapeutics's assets?
Raw Data
NasdaqGS:YMAB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $3.67
NasdaqGS:YMAB Share Price * NasdaqGS (2019-07-19) in USD $22.78
United States of America Biotechs Industry PB Ratio Median Figure of 437 Publicly-Listed Biotechs Companies 2.93x
United States of America Market PB Ratio Median Figure of 5,248 Publicly-Listed Companies 1.79x
NasdaqGS:YMAB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:YMAB Share Price ÷ Book Value per Share (both in USD)

= 22.78 ÷ 3.67

6.21x

* Primary Listing of Y-mAbs Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Y-mAbs Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Y-mAbs Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Y-mAbs Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Y-mAbs Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Y-mAbs Therapeutics expected to grow at an attractive rate?
  • Unable to compare Y-mAbs Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Y-mAbs Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Y-mAbs Therapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:YMAB Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:YMAB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 11.7%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:YMAB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:YMAB Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31
2022-12-31 387 1
2021-12-31 157 2
2020-12-31 44 -42 -52 2
2019-12-31 0 -61 -68 5
NasdaqGS:YMAB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -48 -52
2018-12-31 -41 -43
2018-09-30 -34 -38
2018-06-30 -27 -31
2018-03-31 -19 -24
2017-12-31 -16 -19
2016-12-31 -11 -17

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Y-mAbs Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Y-mAbs Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:YMAB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Y-mAbs Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:YMAB Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 -1.68 -1.43 -1.95 3.00
2019-12-31 -2.00 -1.94 -2.12 4.00
NasdaqGS:YMAB Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.69
2018-12-31 -1.50
2018-09-30 -1.46
2018-06-30 -1.29
2018-03-31 -1.09
2017-12-31 -0.99
2016-12-31 -1.21

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Y-mAbs Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Y-mAbs Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Y-mAbs Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Y-mAbs Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Y-mAbs Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Y-mAbs Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Y-mAbs Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Y-mAbs Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Y-mAbs Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Y-mAbs Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:YMAB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -51.73 11.53 40.48
2018-12-31 -43.27 8.96 34.27
2018-09-30 -38.47 8.57 29.85
2018-06-30 -30.87 6.66 24.20
2018-03-31 -23.60 5.45 18.21
2017-12-31 -19.16 4.94 14.31
2016-12-31 -17.06 3.18 13.86

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Y-mAbs Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Y-mAbs Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Y-mAbs Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Y-mAbs Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Y-mAbs Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Y-mAbs Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Y-mAbs Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Y-mAbs Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Y-mAbs Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Y-mAbs Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Y-mAbs Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Y-mAbs Therapeutics Company Filings, last reported 3 months ago.

NasdaqGS:YMAB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 125.51 0.00 134.25
2018-12-31 140.53 0.00 147.84
2018-09-30 155.03 0.00 163.29
2018-06-30 65.52 0.00 70.15
2018-03-31 82.15 0.00 90.48
2017-12-31 82.15 0.00 90.48
2016-12-31 12.06 0.00 16.88
  • Y-mAbs Therapeutics has no debt.
  • Y-mAbs Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Y-mAbs Therapeutics has sufficient cash runway for 2.8 years based on current free cash flow.
  • Y-mAbs Therapeutics has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 60.6% each year.
X
Financial health checks
We assess Y-mAbs Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Y-mAbs Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Y-mAbs Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Y-mAbs Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Y-mAbs Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Y-mAbs Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Y-mAbs Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:YMAB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 18 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:YMAB Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Y-mAbs Therapeutics has not reported any payouts.
  • Unable to verify if Y-mAbs Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Y-mAbs Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Y-mAbs Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Y-mAbs Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Y-mAbs Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Y-mAbs Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Y-mAbs Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Y-mAbs Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Claus Møller San Pedro
COMPENSATION $4,226,938
AGE 57
TENURE AS CEO 4.1 years
CEO Bio

Dr. Claus Juan Møller San Pedro, M.D., Ph.D. has been Chief Executive Officer of Y-mAbs Therapeutics, Inc. since June 2015 and serves as its Director. Dr. Møller was the founder of Azanta A/S, or Azanta, a Danish specialty biopharmaceutical company and its Chief Executive Officer from 2009 to 2015. In addition, Dr. Møller co-founded Genmab A/S, or Genmab, one of the largest European biopharmaceutical companies in 1999, where he served as Executive Vice President and Chief Operating Officer until 2008. Dr. Møller has also held previous executive management positions at various biopharmaceutical companies, including Executive Vice President, Chief Medical and Chief Operating Officer of OXiGENE, Inc., and Medical Director of Synthélabo Scandinavia. Dr. Møller received his M.D. and Ph.D. degrees from the University of Copenhagen.

CEO Compensation
  • Claus's compensation has increased whilst company is loss making.
  • Claus's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Y-mAbs Therapeutics management team in years:

3.8
Average Tenure
52
Average Age
  • The tenure for the Y-mAbs Therapeutics management team is about average.
Management Team

Thomas Gad

TITLE
Founder
COMPENSATION
$3M
AGE
49
TENURE
4.3 yrs

Claus Møller San Pedro

TITLE
CEO & Director
COMPENSATION
$4M
AGE
57
TENURE
4.1 yrs

Bo Kruse

TITLE
Executive VP
COMPENSATION
$2M
AGE
46
TENURE
4.1 yrs

Joris Wiel Wilms

TITLE
Senior VP & COO
AGE
44
TENURE
1.7 yrs

Torben Lund-Hansen

TITLE
Senior VP & Head of Technical Operations
AGE
68
TENURE
3.5 yrs

Steen Lisby

TITLE
Senior VP & Chief Medical Officer
AGE
55
TENURE
2.1 yrs
Board of Directors Tenure

Average tenure and age of the Y-mAbs Therapeutics board of directors in years:

1.7
Average Tenure
51.5
Average Age
  • The average tenure for the Y-mAbs Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Claus Møller San Pedro

TITLE
CEO & Director
COMPENSATION
$4M
AGE
57

Jim Healy

TITLE
Director
COMPENSATION
$221K
AGE
54
TENURE
1.7 yrs

Thomas Gad

TITLE
Founder
COMPENSATION
$3M
AGE
49
TENURE
4.3 yrs

Ashu Tyagi

TITLE
Director
COMPENSATION
$12K
AGE
42
TENURE
1.7 yrs

David Gill

TITLE
Director
COMPENSATION
$223K
AGE
64
TENURE
1.6 yrs

Johan Wedell-Wedellsborg

TITLE
Director
COMPENSATION
$220K
AGE
49
TENURE
3.8 yrs

Gregory Raskin

TITLE
Director
COMPENSATION
$222K
AGE
46
TENURE
3.8 yrs

Gérard Ber

TITLE
Independent Director
COMPENSATION
$403K
AGE
61
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
11. Apr 19 Sell Thomas Gad Individual 09. Apr 19 11. Apr 19 -250,000 $26.93 $-6,472,729
26. Sep 18 Buy Scopia Capital Management LP Company 25. Sep 18 25. Sep 18 430,174 $16.00 $6,882,784
26. Sep 18 Buy Sofinnova Investment, Inc. Company 21. Sep 18 21. Sep 18 500,000 $16.00 $8,000,000
25. Sep 18 Buy Claus Juan Moller San Pedro Individual 25. Sep 18 25. Sep 18 31,250 $16.00 $500,000
X
Management checks
We assess Y-mAbs Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Y-mAbs Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Did Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insiders Sell Shares?

So we'll take a look at whether insiders have been buying or selling shares in Y-mAbs Therapeutics, Inc. … Check out our latest analysis for Y-mAbs Therapeutics Y-mAbs Therapeutics Insider Transactions Over The Last Year In the last twelve months, the biggest single sale by an insider was when the Founder, Thomas Gad, sold US$6.5m worth of shares at a price of US$26.93 per share. … It's great to see high levels of insider ownership, but looking back at the last year, we don't gain confidence from the Y-mAbs Therapeutics insiders selling.

Simply Wall St -

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB): Are Analysts Bullish?

The latest earnings announcement Y-mAbs Therapeutics, Inc. … (NASDAQ:YMAB) released in December 2018 … that losses became smaller relative to the prior year's level

Simply Wall St -

How Much Are Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insiders Spending On Buying Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Y-mAbs Therapeutics, Inc. … The Last 12 Months Of Insider Transactions At Y-mAbs Therapeutics … In the last twelve months, the biggest single purchase by an insider was when Claus Juan Moller San Pedro bought US$500k worth of shares at a price of US$16.00 per share

Simply Wall St -

Do Insiders Own Shares In Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)?

A look at the shareholders of Y-mAbs Therapeutics, Inc. … With a market capitalization of US$679m, Y-mAbs Therapeutics is a small cap stock, so it might not be well known by many institutional investors. … Check out our latest analysis for Y-mAbs Therapeutics

Simply Wall St -

Company Info

Description

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.

Details
Name: Y-mAbs Therapeutics, Inc.
YMAB
Exchange: NasdaqGS
Founded: 2015
$778,931,711
34,193,666
Website: http://www.ymabs.com
Address: Y-mAbs Therapeutics, Inc.
230 Park Avenue,
Suite 3350,
New York,
New York, 10169,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS YMAB Common Stock Nasdaq Global Select US USD 21. Sep 2018
Number of employees
Current staff
Staff numbers
32
Y-mAbs Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/22 03:28
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/07/10
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.